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Introduction 
Fine needle aspiration (FNA) is a widely used 
technique (l-3). We describe our experience using 
FNA in patients with palpable, probably metastatic, 
processes from suspected primary lung cancer. 
Patients and Methods 
Forty-nine patients (36 male, 13 female, mean age 
66 years, range 42-8 1 years) were studied. Thirty-one 
patients had enlarged lymph nodes and 18 patients 
had subcutaneous lumps unrelated to lymph 
nodes. Nine patients had previously undergone an 
inconclusive bronchoscopy. 
The FNA sample was taken with a 23-g needle 
attached to a lo-ml syringe which was introduced 
into the mass and gently moved within the lesion 
while gentle suction was applied. During the later 
part of the study, 13 consecutive patients were asked 
to complete a brief questionnaire after the sample 





Please choose a number between O-10 which 
indicates how painful you found it. No pain at 
all = 0, worst pain imaginable = 10. 
How do you think it compares with having a 
normal blood test done? 
More painful 
About the same 
Less painful 
Apart from pain did you find it unpleasant? If so 
please explain why. 
Would you be prepared to have the test repeated? 
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Results 
Malignant cells were identified in all samples 
except four. One was adenocarcinoma, 1.5 were 
squamous, 19 were undifferentiated including large 
cells, 10 were oat cell and 1 was Hodgkins. In one 
patient, the initial sample taken from a neck gland 
was negative but a further FNA of a subcutaneous 
lump on the back showed malignant squamous cells. 
In three other patients, no malignant cells were 
identified. The subsequent clinical course suggested 
that these were true negatives. 
Confirmatory pathology is available in 18 patients. 
Details are given in Table 1. Pain scores ranged from 
o-6. The median was only 1. 
Only one patient found the FNA more painful 
than a normal blood sample. No one described it as 
unpleasant, apart from pain, and all were prepared to 
have it repeated. 
Considering all patients, survival varied from less 
than 1 week to about 4yr (4yr survival being in a 
patient who subsequently turned out to have an 
atypical carcinoid) with a median of only 6 weeks. 
For patients with subcutaneous (i.e. non-lymph 
gland) lesions, the median survival was only 4 weeks 
(range less than 140 weeks). 
Discussion 
This study showed that FNA in this group of 
patients is a highly sensitive method of diagnosing 
metastatic malignant disease. 
The technique is simple and usually causes minimal 
discomfort. It can easily be done on an outpatient 
or even a domiciliary basis, which is particularly 
important in patients with such a poor prognosis. 
It is also cheaper than both surgical biopsy and 
bronchoscopy. 
Confirmatory pathology was only available in a 
minority of patients. It was usually unjustified to do 
further tests in this group of seriously ill patients with 
metastases from a probable lung primary. A good 
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Table 1 Confirmatory pathology* 
Atypical 
carcinoid (well 
Undifferentiated Oat differentiated 
FNA diagnosis Squamous including large cell cell Hodgkins Adenocarcinoma Mesothelioma neuroendocrine) 
Squamous 4 1 
Undifferentiated 4 1 1 1 
including large 
Cdl 
Oat cell 1 4 
Hodgkins 1 
*Confirmatory pathology was: 
Bronchoscopy 6 patients (including one patient who had gland biopsy also) 
Post-mortem 5 
Surgical gland biopsy 2 
sputum cytology 4 
Pleural fluid cytology 1 
Previous pneumonectomy 1 
correlation has been shown between FNA cytology 
of intrathoracic lung cancer and subsequent path- 
ology (4), particularly in patients with small cell 
carcinoma (5). Samples taken from easily palpable 
metastases should be at least as accurate. In practice, 
the exact cell type may not matter much. Patients 
with small cell cancer and good performance status 
may do well with chemotherapy (6) but only two 
of our 10 patients were thought to be fit enough 
to receive intravenous chemotherapy and neither 
did well. 
Although suggested by some authors (7), we do 
not use chemotherapy in patients with non-small 
cell cancer and the use of palliative radiotherapy 
is similar (6). 
In summary, this study showed FNA to be a highly 
sensitive method of confirming metastatic malig- 
nant disease, and causes minimal discomfort. It 
should be the initial diagnostic technique for these 
unfortunate patients. 
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